A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

Azam Doustmohammadian; Ahmad Nezhadisalami; Fahimeh Safarnezhad Tameshke; Nima Motamed; Mansooreh Maadi; Mohammad Farahmand; Masoudreza Sohrabi; Cain C.T. Clark; Hossein Ajdarkosh; Amir Hossein Faraji; Mehdi Nikkhah; Elham Sobhrakhshankhah; Ramin Ebrahimi; Farhad Zamani

doi:10.3389/fmed.2022.937554

A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

Azam Doustmohammadian, Ahmad Nezhadisalami, Fahimeh Safarnezhad Tameshke, Nima Motamed, Mansooreh Maadi, Mohammad Farahmand, Masoudreza Sohrabi, Cain C.T. Clark, Hossein Ajdarkosh, Amir Hossein Faraji, Mehdi Nikkhah, Elham Sobhrakhshankhah, Ramin Ebrahimi, Farhad Zamani^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

8 Citations (SciVal)

Original language	English
Article number	937554
Journal	Frontiers in Medicine
Volume	9
DOIs	https://doi.org/10.3389/fmed.2022.937554
Publication status	Published (VoR) - 28 Jul 2022

Funding

This work was funded by the Gastrointestinal and liver Diseases Research Center (GILDRC), Iran University of Medical Sciences (IUMS) (grant no. 97-3-30-13227).

Funders	Funder number
Iran University of Medical Sciences	97-3-30-13227
Gastrointestinal and Liver Diseases Research Center

Keywords

clinical trial design
fibrosis scores
liver enzymes
NAFLD
sitagliptin

Access to Document

10.3389/fmed.2022.937554

Cite this

Doustmohammadian, A., Nezhadisalami, A., Safarnezhad Tameshke, F., Motamed, N., Maadi, M., Farahmand, M., Sohrabi, M., Clark, C. C. T., Ajdarkosh, H., Faraji, A. H., Nikkhah, M., Sobhrakhshankhah, E., Ebrahimi, R., & Zamani, F. (2022). A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes. Frontiers in Medicine, 9, Article 937554. https://doi.org/10.3389/fmed.2022.937554

@article{31d62f95baaf472d92b8e9e50869607c,

title = "A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes",

keywords = "clinical trial design, fibrosis scores, liver enzymes, NAFLD, sitagliptin",

author = "Azam Doustmohammadian and Ahmad Nezhadisalami and {Safarnezhad Tameshke}, Fahimeh and Nima Motamed and Mansooreh Maadi and Mohammad Farahmand and Masoudreza Sohrabi and Clark, {Cain C.T.} and Hossein Ajdarkosh and Faraji, {Amir Hossein} and Mehdi Nikkhah and Elham Sobhrakhshankhah and Ramin Ebrahimi and Farhad Zamani",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 Doustmohammadian, Nezhadisalami, Safarnezhad Tameshke, Motamed, Maadi, Farahmand, Sohrabi, Clark, Ajdarkosh, Faraji, Nikkhah, Sobhrakhshankhah, Ebrahimi and Zamani.",

year = "2022",

month = jul,

day = "28",

doi = "10.3389/fmed.2022.937554",

language = "English",

volume = "9",

journal = "Frontiers in Medicine",

issn = "2296-858X",

publisher = "Frontiers Media",

}

Doustmohammadian, A, Nezhadisalami, A, Safarnezhad Tameshke, F, Motamed, N, Maadi, M, Farahmand, M, Sohrabi, M, Clark, CCT, Ajdarkosh, H, Faraji, AH, Nikkhah, M, Sobhrakhshankhah, E, Ebrahimi, R & Zamani, F 2022, 'A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes', Frontiers in Medicine, vol. 9, 937554. https://doi.org/10.3389/fmed.2022.937554

A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes. / Doustmohammadian, Azam; Nezhadisalami, Ahmad; Safarnezhad Tameshke, Fahimeh et al.
In: Frontiers in Medicine, Vol. 9, 937554, 28.07.2022.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

AU - Doustmohammadian, Azam

AU - Nezhadisalami, Ahmad

AU - Safarnezhad Tameshke, Fahimeh

AU - Motamed, Nima

AU - Maadi, Mansooreh

AU - Farahmand, Mohammad

AU - Sohrabi, Masoudreza

AU - Clark, Cain C.T.

AU - Ajdarkosh, Hossein

AU - Faraji, Amir Hossein

AU - Nikkhah, Mehdi

AU - Sobhrakhshankhah, Elham

AU - Ebrahimi, Ramin

AU - Zamani, Farhad

N1 - Publisher Copyright: Copyright © 2022 Doustmohammadian, Nezhadisalami, Safarnezhad Tameshke, Motamed, Maadi, Farahmand, Sohrabi, Clark, Ajdarkosh, Faraji, Nikkhah, Sobhrakhshankhah, Ebrahimi and Zamani.

PY - 2022/7/28

Y1 - 2022/7/28

KW - clinical trial design

KW - fibrosis scores

KW - liver enzymes

KW - NAFLD

KW - sitagliptin

UR - http://www.scopus.com/inward/record.url?scp=85135856810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85135856810&partnerID=8YFLogxK

U2 - 10.3389/fmed.2022.937554

DO - 10.3389/fmed.2022.937554

M3 - Article

AN - SCOPUS:85135856810

SN - 2296-858X

VL - 9

JO - Frontiers in Medicine

JF - Frontiers in Medicine

M1 - 937554

ER -

A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this